HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elizabeth Cairns

Senior Writer

A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.

Latest From Elizabeth Cairns

Taking On Vyvgart In Myasthenia Gravis

Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.

Inflammation Clinical Trials

Remibrutinib REMIXes The Itch Record

Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.

Clinical Trials Companies

GSK Counters Innoviva’s Gonorrhea Hit

Both groups have posted hits with similar novel antibiotics, and both have a lot riding on commercial success.

Clinical Trials Companies

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

Clinical Trials Commercial

Iovance Lucks Out With Amtagvi

The long-delayed accelerated approval of the melanoma T-cell therapy comes a week early, and with a generous label.

Approvals Cancer

Inventiva Craters On NASH Safety Scare

An adverse reaction in lanafibranor’s Phase III trial leaves the company even more reliant on the upcoming LEGEND readout. 

Clinical Trials Companies
See All
UsernamePublicRestriction

Register